medigraphic.com
Instituto Nacional de Salud Pública

2017, Número 5

<< Anterior Siguiente >>

salud publica mex 2017; 59 (5)


Variantes genéticas de CYP1A1, CYP1B1, GSTM1 y GSTT1, y riesgo de cáncer mamario en mujeres mexicanas

García-Martínez A, Gamboa-Loira B, Tejero ME, Sierra-Santoyo A, Cebrián ME, López-Carrillo L

Idioma: Ingles.
Referencias bibliográficas: 27
Paginas: 540-547
Archivo PDF: 322.28 Kb.


RESUMEN

Objetivo. Evaluar si las variantes en los genes CYP1A1 (T3801C y A4889G), CYP1B1 (G119T), GSTM1 (indel) yGSTT1 (indel), se asocian con el cáncer de mama (CM) en mujeres mexicanas. Material y métodos. Se parearon por edad (± 5 años) y zona de residencia 952 casos incidentes de CM histológicamente confirmado con 998 controles sanos poblacionales. Se genotipificaron variantes en los genes CYP1A1, CYP1B1, GSTM1 y GSTT1 por discriminación alélica y PCR multiplex. En una submuestra de mujeres, se determinaron 105 marcadores de ancestría. Resultados. Se observó un aumento del riesgo de CM, independiente de otros factores de riesgo, entre las portadoras del genotipo CYP1B1 G119T (T/T vs. G/G: RM=1.9; 95%CI 1.4-2.5). Conclusiones. Nuestros resultados soportan la existencia de susceptibilidad genética para CM conferida por la variante CYP1B1 G119T en mujeres mexicanas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bray F, Piñeros M. Cancer patterns, trends and projections in Latin America and the Caribbean: a global context. Salud Publica Mex. 2016;58:104-17. https://doi.org/10.21149/spm.v58i2.7779

  2. Ghiasvand R, Adami HO, Harirchi I, Akrami R, Zendehdel K. Higher incidence of premenopausal breast cancer in less developed countries; myth or truth? BMC Cancer. 2014;14(1):343. https://doi.org/10.1186/1471- 2407-14-343

  3. Williams JA, Phillips DH. Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer role in breast cancer 1. Cancer Res. 2000;60:4667-77.

  4. López-Carrillo L, Hernández-Ramírez RU, Gandolfi AJ, Ornelas-Aguirre JM, Torres-Sánchez L, Cebrian ME. Arsenic methylation capacity is associated with breast cancer in northern Mexico. Toxicol Appl Pharmacol. 2014;280(1):53-9. https://doi.org/10.1016/j.taap.2014.07.013

  5. Thermo Fisher Scientific. NanoDrop Spectrophotometers. Assessment of Nucleic Acid Purity [Internet]. Wilmington, Delaware: Thermo Fisher Scientific Inc, 2012 [cited september 3, 2016]. Available from: http://www. nanodrop.com/Library/T042-NanoDrop-Spectrophotometers-Nucleic- Acid-Purity-Ratios.pdf

  6. Xiong P, Bondy ML, Li D, Xiong P, Bondy ML, Li D, et al. Sensitivity to Benzo(a)pyrene Diol-Epoxide associated with risk of breast cancer in young women and modulation by Glutathione S-Transferase Polymorphisms: A case-control study. Cancer Res. 2001;61:8465-9.

  7. Galanter JM, Fernandez-Lopez JC, Gignoux CR, Barnholtz-Sloan J, Fernandez-Rozadilla C, Via M, et al. Development of a panel of genomewide ancestry informative markers to study admixture throughout the Americas. PLoS Genet. 2012;8(3):e1002554. https://doi.org/10.1371/journal. pgen.1002554

  8. Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in unrelated individuals. Genome Res. 2009;19(9):1655-64. https://doi.org/10.1101/gr.094052.109

  9. Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22(15):1928-9. https:// doi.org/10.1093/bioinformatics/btl268

  10. Day SE, Hinterland K, Myers C, Gupta L, Harris TG, Konty KJ. A school-level proxy measure for individual-level poverty using school-level eligibility for free and reduced-price meals. J Sch Health. 2016;86(3):204- 14. https://doi.org/10.1111/josh.12371

  11. Li C, Long B, Qin X, Li W, Zhou Y. Cytochrome P1B1 (CYP1B1) polymorphisms and cancer risk: A meta-analysis of 52 studies. Toxicology. 2015;327(2):77-86. https://doi.org/10.1016/j.tox.2014.11.007

  12. Economopoulos KP, Sergentanis TN. Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: A meta-analysis. Breast Cancer Res Treat. 2010;122(2):545-51. https://doi.org/10.1007/ s10549-009-0728-z

  13. Qiu LX, Yuan H, Yu K Da, Mao C, Chen B, Zhan P, et al. Glutathione S-transferase M1 polymorphism and breast cancer susceptibility: A meta-analysis involving 46,281 subjects. Breast Cancer Res Treat. 2010;121(3):703-8. https://doi.org/10.1007/s10549-009-0636-2

  14. Zhang B, Beeghly-Fadiel A, Long J, Zheng W. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, metaanalysis, and epidemiological evidence. Lancet Oncol. 2011;12(5):477-88. https://doi.org/10.1016/S1470-2045(11)70076-6

  15. Jaramillo-Rangel G, Ortega-Martínez M, Cerda-Flores R, Barrera- Saldaña H. Polymorphisms in GSTM1, GSTT1, GSTP1 and GSTM3 genes and breast cancer risk in northeastern Mexico. Genet Mol Res. 2015;14(2):6465-71. https://doi.org/10.4238/2015.June.11.22

  16. Institute of Medicine. Breast cancer and the environment: A life course approach. Washington, DC: The National Academies Press, 2012:469.

  17. Landi M, Bertazzi P, Shields P, Clark G, Lucier G, Garte S, et al. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics. 1994;4(5):242-6. https://doi. org/10.1097/00008571-199410000-00002

  18. Masson LF, Sharp L, Cotton SC, Little J. Cytochrome P-450 1A1 Gene Polymorphisms and risk of breast cancer: a HuGE review. Am J Epidemiol. 2005;161(10):901-15. https://doi.org/10.1093/aje/kwi121

  19. Chen C, Huang Y, Li Y, Mao Y, Xie Y. Cytochrome P450 1A1 (CYP1A1) T3801C and A2455G polymorphisms in breast cancer risk: A metaanalysis. J Hum Genet. 2007;52(5):423-35. https://doi.org/10.1007/s10038- 007-0131-8

  20. Sergentanis TN, Economopoulos KP. Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;122(2):459-69. https://doi.org/10.1007/ s10549-009-0694-5

  21. Yao L, Yu X, Yu L. Lack of significant association between CYP1A1 T3801C polymorphism and breast cancer risk: A meta-analysis involving 25,087 subjects. Breast Cancer Res Treat. 2010;122(2):503-7. https://doi. org/10.1007/s10549-009-0717-2

  22. He XF, Wei W, Liu ZZ, Shen XL, Yang X Bin, et al. Association between the CYP1A1 T3801C polymorphism and risk of cancer: Evidence from 268 case-control studies. Gene. 2014;534(2):324-44. https://doi. org/10.1016/j.gene.2013.10.025

  23. Martínez-Ramírez OC, Pérez-Morales R, Castro C, Flores-Díaz A, Soto-Cruz KE, et al. Polymorphisms of catechol estrogens metabolism pathway genes and breast cancer risk in Mexican women. Breast. 2013;22(3):335-43. https://doi.org/10.1016/j.breast.2012.08.004

  24. Vogl FD, Taioli E, Maugard C, Zheng W, Pinto LFR, Ambrosone C, et al. Glutathione S-tranferases M1, T1, and P1 and Breast Cancer: A Pooled Analysis. Cancer Epidemiol biomarkers Prev. 2004;13(9):1473-9.

  25. Egan KM, Cai Q, Shu X, Jin F. Genetic Polymorphisms in GSTM1 , GSTP1, and GSTT1 and the Risk for Breast Cancer: Results from the Shanghai Breast Cancer Study and Meta-Analysis. Cancer Epidemiol Biomarkers Prev. 2004;13(2):197-204. https://doi.org/10.1158/1055-9965. EPI-03-0294

  26. Chen XX, Zhao RP, Qiu LX, Yuan H, Mao C, Hu XC, et al. Glutathione S-transferase T1 polymorphism is associated with breast cancer susceptibility. Cytokine. 2011;56(2):477-80. https://doi.org/10.1016/j. cyto.2011.06.008

  27. Song Z, Shao C, Feng C, Lu Y, Gao Y, Dong C. Association of glutathione S-transferase T1, M1 and P1 polymorphisms in the breast cancer risk: A meta-analysis in Asian population. Ther Clin Risk Manag. 2016;12:763-9. https://doi.org/10.2147/TCRM.S104339




2020     |     www.medigraphic.com